Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the use of ruxolitinib (Jakafi) as a second-line treatment for patients with polycythemia vera (PV).
For the second-line setting in PV, patients typically have a shorter survival, said Verstovsek. At this stage, the disease is more aggressive and a second line of therapy is needed.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More